Minapharm Pharmaceuticals results, Q2 2021
Net profit, assets, equity and cash flow for Q2 2021, against the same period a year earlier, from the published financial statements.
Net profit130 millionEGP
Total assets3.85 billionEGP
Shareholders' equity1.76 billionEGP
Operating cash flow50.56 millionEGP
In short
- Minapharm Pharmaceuticals's net profit for Q2 2021 was about 130 million EGP.
- Total assets at the end of Q2 2021 were about 3.85 billion EGP, and shareholders' equity about 1.76 billion EGP.
- Operating cash flow for Q2 2021 was positive at 50.56 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit130 million——
Gross profit318 million——
Total assets3.85 billion——
Total liabilities2.09 billion——
Shareholders' equity1.76 billion——
Total liabilities and equity3.85 billion——
Operating cash flow50.56 million——
Investing cash flow-51.32 million——
Financing cash flow67.71 million——
Net change in cash66.96 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy